Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant's Dermatology Sales Strategy: Teenage Zits

Executive Summary

Valeant Pharmaceutical International Inc.'s dermatology business is in trouble. But CEO Joseph Papa said the company is counting on teenagers eager to have clear skin when they return to school in the fall to boost prescriptions of the firm's acne medicine Solodyn (minocycline).


Related Content

Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
Valeant's New Strategic Direction: Clean Break Or Simply A Paint Job?
Valeant Reset: Will It Cure What Ails It?
Regrets For Valeant's Ackman, Pearson; Big Pay For Papa


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts